Navigation Links
Pharmacyclics Announces Promising Results From Phase 2 Clinical,Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung,Cancer

n of response in patients with recurrent NSCLC who are treated with Xcytrin. Patients in the trial are randomized to receive either a 10mg/kg dose of Xcytrin every week, or a 15mg/kg dose every three weeks. Tumor response rate is being evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), the standard parameters used to document response for solid tumors.

Of 58 evaluable patients there was a confirmed response rate of 5.2%, or three partial responses. Twenty patients (34.5%) had stable disease. One of the responders received Xcytrin after having progressed through two prior lines of therapy: carboplatin, gemcitabine and bevacizumab, followed by erlotinib. The other two had previously failed either carboplatin/gemcitabine or cisplatin/vinorelbine. Median time to progression was seven weeks for all patients. Twenty (34.5%) patients received four or more cycles of Xcytrin, of whom seven did not respond to first line chemotherapy. Thirteen percent were free from progression at six months. Median survival was eight months, with 62% and 30% of patients alive at 6 and 12 months, respectively. Xcytrin was well-tolerated in this study. The most common grade 3 or 4 adverse events were hypophosphatemia (24%), dyspnea (12%), fatigue (10%), hypoxia (7%), and finger blisters (5%).

About Non-Small Cell Lung Cancer

The American Cancer Society predicts that there will be more than 213,000 new cases of lung cancer in the U.S. in 2007. Lung cancer is the leading cause of cancer death, and accounts for over 160,000 deaths in the U.S. each year. The most common form of lung cancer, non-small cell, is incurable in advanced stages. Lung cancer frequently spreads to other body parts, including the brain.

Xcytrin in Second-Line Lung Cancer

Pharmacyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, ... the American Association of Tissue Banks (AATB), it ... Chief Executive Officer. Accreditation follows an ... a specially trained AATB inspector.  It establishes that ... within the facility meets or exceeds the standards ...
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional ... towels and tissue for a wide range of ... of its product lines in healthcare, including hospitals, ... Georgia-Pacific Professional is introducing its healthcare products and ... Professional understands the importance of infection control in ...
(Date:9/30/2014)... , Sept. 30, 2014 Passport Health, one ... , has launched FluFree.com, a website designed to ... For 20 years, Passport Health has provided ... flu. The launch of FluFree.com is designed to address ... the number of people who actually chose to get ...
Breaking Medicine Technology:Biostructures, LLC Earns AATB Accreditation 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3
... Jan. 23, 2012  PLC Systems Inc. (OTC: PLCSF), a ... successful enrollment of the first patient in the CIN-RG ... of its RenalGuard Therapy® and RenalGuard System™ in the ... step in the process to secure regulatory approval by ...
... EntreMed, Inc. (Nasdaq: ENMD ), a ... of cancer, announced today that it has secured ... including IDG-Accel China Growth Fund II L.P. ("IDG"), ... W. Mak, Director of The Campbell Family Institute ...
Cached Medicine Technology:First Patient Treated in PLC Systems' RenalGuard® U.S. Pivotal Trial 2First Patient Treated in PLC Systems' RenalGuard® U.S. Pivotal Trial 3EntreMed Secures $10 Million Strategic Financing 2EntreMed Secures $10 Million Strategic Financing 3EntreMed Secures $10 Million Strategic Financing 4EntreMed Secures $10 Million Strategic Financing 5
(Date:9/30/2014)... September 30, 2014 A group of Americans ... combat an epidemic that, left unchecked, could create a catastrophic, ... not headed to Africa. John Rogers, the Executive Director the ... Korea to fight a disease most think mankind conquered long ... 80 years ago is on the comeback in several countries ...
(Date:9/30/2014)... Beach, Florida (PRWEB) September 30, 2014 Two ... make the treatment of gum disease a far ... of the past. , “If you’ve ever felt electric shock ... cream or sip a cold beverage, it’s possible you already ... Salisbury , who is a general dentist in West Palm ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Medicare should cover low-dose computed ... for the disease, a coalition of more than 60 ... includes the Lung Cancer Alliance, the Society of Thoracic ... Society and the American Society of Clinical Oncology, made ... U.S. Centers for Medicare & Medicaid Services (CMS). ...
(Date:9/30/2014)... of Defense has made progress in reducing the stigma ... depression and post-traumatic stress disorder, but more improvement is ... , Despite efforts of both the Defense Department and ... many service members still do not seek needed care ... a concerted effort to promote treatment as a way ...
(Date:9/30/2014)... ANN ARBORThe discovery of a gene mutation that causes ... development of drugs that block the rapid, unstoppable cell ... at the University of Michigan and the U-M Health ... devastating disease dyskeratosis congenita, in which precious hematopoietic stem ... DC age prematurely and are prone to cancer and ...
Breaking Medicine News(10 mins):Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2
... , TUESDAY, Jan. 12 (HealthDay News) -- An experimental ... study shows. , The drug, DBZ, currently in clinical ... have side effects on the lining of the lower ... to those seen in Barrett,s esophagus, a condition that ...
... two ,good, copies slows age-linked mental decline by half, study ... variant that is good for the heart also appears to ... function and cutting the odds for Alzheimer,s disease, a study ... form of the gene, it reduces the risk of Alzheimer,s ...
... ... and Normal Lives Due to Groundbreaking Gene Therapy, , ... Cambridge, MA (Vocus) January 12, 2010 -- Genetix Pharmaceuticals, a leader ... ALD gene therapy research recently published by its collaboratiors at National Institute of Health and ...
... , WATERTOWN, Mass. , Jan. 12 ... cardiovascular system is also good for the brain, according to ... been braving cold temperatures to get in shape for the ... are encouraging others to keep in shape as well. , ...
... 5, 2010An enzyme that normally helps break down stored ... them more malignant, according to new findings by a ... has focused on the mechanisms leading to cancer formation ... says Benjamin Cravatt, chair of the Scripps Research Department ...
... , , SHENZHEN, China , ... www.htdsmedical.com ) announced that its directors have resolved that up ... sale of its MindUp division to Hiru will be distributed to ... Terry Yuan , HTDS President, said, "In our efforts to maximize ...
Cached Medicine News:Health News:Gene Variant Could Lower Alzheimer's Risk 2Health News:Gene Variant Could Lower Alzheimer's Risk 3Health News:Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009 2Health News:Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009 3Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 2Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 3Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 4Health News:Scripps Research scientists find cancer cells co-opt fat metabolism pathway to become more malignant 2Health News:Scripps Research scientists find cancer cells co-opt fat metabolism pathway to become more malignant 3Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 2Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 3Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: